

AMENDMENTS TO THE CLAIMS

Claims 1 to 22 (cancelled)

Claim 23 (currently amended)

A lipopeptide comprising at least one auxiliary T epitope, at least one CTL epitope and ~~at least one lipid moiety wherein the epitope and the lipid moiety~~ consists of a unbranched or branched, unsaturated or saturated, chain derived from fatty acids of 10 to 20 carbon atoms;

the at least one CTL epitope consists of a CTL epitope of a HIV protein;
and wherein

the lipid moiety and the epitopes are separated by hydrophilic aminoacid spacer chain having a length of 1 to 10 aminoacids, said aminoacids being independently selected from glycine, arginine, glutamic acid, asparatic acid and cysteine; or

two distinct epitopes are separated by a hydrophilic aminoacid spacer chain having a length of 1 to 10 aminoacids, said aminoacids being independently selected from glycine, arginine, glutamic acid, aspartic acid and cysteine; or

both the lipid moiety and the epitopes on the one hand, and the epitopes, on the other hand, are separated by an aminoacid spacer chain having a length of 1 to 10 aminoacids, said aminoacids being independently selected from glycine, arginine, glutamic acid, aspartic acid and cysteine ~~are independently separated from the epitopes by amino acid sequences (spacers) comprising linkages of charged amino acids in a neutral membrane to render the lipopeptide hydrophilic.~~

Claim 24 (cancelled)

Claim 25 (currently amended)

A lipopeptide of claim 23 wherein at least one of the amino acid spacer ~~spacers~~ chains is least one member of the group consisting of 1 to 10 glycines and arginines.

Claim 26 (currently amended)

A lipopeptide of claim 23 wherein at least one amino acid spacer chain is selected from the group consisting of Gly Arg and Arg Gly Arg.

Claim 27 (cancelled)

Claim 28 (currently amended)

A lipopeptide of claim 23 wherein the amino acid ~~spacers~~ spacer chain ~~are~~ ~~comprised of a cysteine or~~ comprises an alkyl functionalized by a thiol and non-peptide bonds.

Claim 29 (currently amended)

A lipopeptide of claim 23 wherein the ~~spacers are~~ amino acid spacer chain comprises a member selected from the group consisting of thiazolidine, oxime ~~or~~ and hydrazone.

Claim 30 (previously presented)

A lipopeptide of claim 23 comprised of a lipid – a first spacer – an auxiliary T epitope – a second spacer – a CTL epitope.

Claim 31 (previously presented)

A lipopeptide of claim 23 comprised of a lipid – a first spacer – auxiliary T epitope – a second spacer – a first CTL epitope – a second CTL epitope.

Claims 32 - 34 (cancelled)

Claim 35 (currently amended)

A lipopeptide of claim 23 wherein the lipid is a moiety selected from the group consisting of palmitic acid, oleic acid, linoleic acid, 2-amino hexadecanoic acid, pimelautide and ~~trimeautide~~ trimexautide.

Claim 36 (previously presented)

A lipopeptide of claim 23 wherein the non-lipid portion is comprised of 15 to 100 amino acids.

Claim 37 (previously presented)

A lipopeptide of claim 23 wherein the auxiliary T epitope is a multivalent epitope.

Claim 38 (previously presented)

A lipopeptide of claim 23 wherein the auxiliary T epitope is the 830-843 peptide of titanic toxin with the sequence QYIKANSKFIGITE.

Claim 39 (previously presented)

A lipopeptide of claim 23 wherein the auxiliary T epitope is haemagglutinin epitope or PADRE epitope.

Claim 40 (cancelled)

Claim 41 (currently amended)

A method of inducing a specific immune response against HIV in a warm-blooded animal comprising administering to a warm-blooded animal an amount of a lipopeptide of claim 23 sufficient to induce a specific immune response.

Claim 42 (cancelled)

Claim 43 (previously presented)

A vaccine comprising an immune inducing effective amount of at least one lipopeptide of claim 23.